Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesMiscellaneous Medical ServicesHCPCS hcpcs-m0238-tocilizumab-infusion-hospitalized-covid19-second-dose
    Ask Trek AI about this page

    HCPCS Level II M0238: Tocilizumab IV Infusion, Second Dose

    HCPCS Level II code M0238 describes a second-dose intravenous infusion of tocilizumab-anoh for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO); service type is drug infusion with post-administration monitoring, and typical site of service is an inpatient hospital setting during the same hospitalization where respiratory support and corticosteroid therapy are provided.

    For related coverage guidance, see recent payer policy updates: Speech Therapy for Autism Disorders - Medical Policy, Physical Performance Test or Measurement, Sensory Integration Therapy and Auditory Integration Training.

    Customize your policy alerts

    Sign up for hcpcs M0238 policy alerts

    Get alerted when payer policies referencing M0238 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A hospitalized adult patient with severe COVID-19 pneumonia is receiving systemic corticosteroids and requires supplemental oxygen delivered by high-flow nasal cannula. The patient has progressive hypoxemia and increasing inflammatory markers (elevated CRP, ferritin) despite standard care. The inpatient medicine team, in coordination with critical care, reviews eligibility for IL-6 receptor antagonist therapy. After verifying indications and contraindications (no active serious bacterial infection, acceptable liver function, and platelet count), the pharmacy prepares an IV dose of tocilizumab-anoh. Nursing administers the infusion in the inpatient unit with continuous pulse oximetry and cardiac monitoring as clinically indicated. The service includes the initial infusion and post-administration monitoring; a second dose is given per protocol if the patient’s condition warrants and per the billing descriptor. Documentation includes indication, baseline vitals and labs, informed consent, drug lot and dose, infusion start/stop times, tolerance, and any adverse reactions. Typical sites of service are the inpatient ward, step-down unit, or intensive care unit, and the service is billed using M0238 with appropriate modifier when required.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    96413Chemotherapy administration, IV infusion technique; up to 1 hour, single or initial substance/drugUsed for IV administration techniques and monitoring when infusion time and observation align with chemotherapy/biologic infusion coding conventions.
    96415Chemotherapy administration, IV infusion technique; each additional hour (List separately in addition to code for primary infusion)Used if infusion monitoring extends beyond the initial hour and facility billing follows infusion time-based add-on reporting.
    96365Intravenous infusion, hydration; initial, 31 minutes to 1 hourMay be reported for simple IV infusion services in some billing workflows when specific biologic administration codes are not applicable; facility-dependent.
    99231Subsequent hospital care, per day, for evaluation and managementRepresents daily inpatient evaluation by the admitting or consulting physician and commonly accompanies biologic administration during hospitalization.
    36415Collection of venous blood by venipunctureUsed for laboratory monitoring before and after tocilizumab infusion (e.g., liver enzymes, CBC, inflammatory markers).

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    54Modifier ‑54 (“Surgical care only”) is appended to a CPT surgical procedure when the reporting surgeon performs the intraoperative (surgical) component but does not furnish the preoperative and/or…- Use modifier -54 when the reporting surgeon provided only the intraoperative (surgical) component of a procedure and preoperative and/or postoperative management has been or will be provided by…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207RH0000X
    208000000X
    2084P0800X
    207K00000X
    208800000X
    208200000X
    207WX0009X
    163WH1000X

    Related ICD-10-CM Codes

    27 rows

    ICD-10-CM CodeDescription
    A41.89Other specified sepsis
    A41.9Sepsis, unspecified organism
    A49.9Bacterial infection, unspecified
    B34.2Coronavirus infection, unspecified
    B34.9Viral infection, unspecified
    B97.29Other coronavirus as the cause of diseases classified elsewhere
    E86.0Dehydration
    G93.0Cerebral cysts
    I21.9Acute myocardial infarction, unspecified
    I46.9Cardiac arrest, cause unspecified

    Showing 1–10 of 27

    Related Payer Policy Updates

    Specialty: Physical Medicine, Rehab & Therapies1 / 3

    10 rows

    PolicyPayerEffective Date
    Speech Therapy for Autism Disorders - Medical PolicyHealth-New-England2026-12-01
    Physical Performance Test or MeasurementCigna2026-11-15
    Sensory Integration Therapy and Auditory Integration TrainingColorado Rocky Mountain Health Plans2026-11-01
    Chiropractic Careexcellus_health_plan_inc2026-10-22
    Skilled Nursing and Skilled Rehabilitation Services (Outpatient)Anthem2026-10-01
    Habilitation and Rehabilitation Therapy (Occupational, Physical, and Speech) (for New Mexico Only)UnitedHealthcare2026-10-01
    Physical Therapy/Medicine Corporate Medical Policybcbsvermont2026-10-01
    Cognitive Rehabilitation Corporate Medical Policybcbsvermont2026-10-01
    Speech Language Pathology/Therapy Services Corporate Medical Policybcbsvermont2026-10-01
    Occupational Therapy Corporate Medical Policybcbsvermont2026-10-01

    Related Codes

    HCPCS-M0075-CELLULAR-THERAPY-PROCESSING-PROVISION

    HCPCS Level II M0075: Cellular Therapy

    HCPCS-M0076-PROLOTHERAPY-INJECTION-THERAPY

    HCPCS Level II M0076: Prolotherapy

    HCPCS-M0100-INTRAGASTRIC-HYPOTHERMIA-GASTRIC-FREEZING

    HCPCS Level II M0100: Intragastric Hypothermia (Gastric Freezing)

    HCPCS-M0201-IN-HOME-VACCINE-ADMINISTRATION

    HCPCS Level II M0201: In-Home Vaccine Administration

    HCPCS-M0220-TIXAGEVIMAB-CILGAVIMAB-PRE-EXPOSURE-PROPHYLAXIS

    HCPCS Level II M0220: Tixagevimab and Cilgavimab Pre-Exposure Prophylaxis

    HCPCS-M0221-TIXAGEVIMAB-CILGAVIMAB-PRE-EXPOSURE-PROPHYLAXIS-HOME-ADMINISTRATION

    HCPCS M0221: Tixagevimab and Cilgavimab Pre-Exposure Prophylaxis

    HCPCS-M0222-BEBTELOVIMAB-INTRAVENOUS-INJECTION-MONITORING

    HCPCS Level II M0222: Bebtelovimab Intravenous Injection with Monitoring

    HCPCS-M0223-BEBTELOVIMAB-INTRAVENOUS-INJECTION-HOME-MONITORING

    HCPCS M0223: Intravenous Bebtelovimab with Home Monitoring

    HCPCS-M0224-PEMIVIBART-PRE-EXPOSURE-PROPHYLAXIS-INFUSION

    HCPCS M0224: Pemivibart Intravenous Infusion for Pre-Exposure Prophylaxis

    HCPCS-M0233-TOCILIZUMAB-INFUSION-COVID19-HOSPITALIZED-ADULTS

    HCPCS Level II M0233: Tocilizumab-aazg IV Infusion, First Dose

    Showing 1–10 of 27

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.